Trivitron Healthcare Private Limited, a leading medical device company providing affordable healthcare solutions to the healthcare industry, has announced the appointment of Rajesh Patel as Chief Executive Officer of In-Vitro Diagnostics [IVD], India business.
Patel is an experienced professional with around 29 years in the areas of sales, marketing & business development in the healthcare segment. He has held a leadership role in global and Indian healthcare companies and has a rich and diverse experience in pharmaceuticals, clinical research, and IVD/Medical Devices segment.
Dr GSK Velu, Chairman and Managing Director, Trivitron Healthcare said. “In his new role, Patel will be at the helm of the company’s IVD business growth and expansion plans. His enthusiastic approach, progressive effort will provide new leadership to the IVD team and will help the division to reach a new milestone. We look forward to an exciting journey along with him and wish him all the success.’’
Also read: Trivitron Healthcare, Sebia hosts Symposium on HbA1c Measurement
Commenting on his appointment, Rajesh Patel, CEO, {IVD- India}, Trivitron Healthcare said, “I am excited by the opportunity to build on the great foundation and momentum achieved by the Trivitron Group and lead the company through the next stage of its strategic development. I am committed to ensure that we not only stay at the forefront in this space but we continue to innovate and lead the market.”
Expressing her delight on the appointment, Chandra Ganjoo, Executive Director, Group CPO & Head Corporate Communications, added, “Rajesh’s strategic leadership, operational excellence expertise in healthcare and passion for innovation will be great assets to us as we grow in the coming years. Mr. Patel will be playing a significant role in reshaping the IVD business and the Trivitron group’s international footprint.”
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.